☰

Salud Bienestar

Pfizer beats fourth quarter forecasts on sales


    (Reuters) - Pfizer Inc reported better than expected fourth-quarter results, helped by sales of new treatments for cancer, nerve pain and arthritis.

    The biggest U.S. drugmaker on Tuesday said it earned $2.57 billion, or 40 cents per share, in the fourth quarter. That compared with $6.32 billion, or 86 cents per share, in the year-earlier quarter, when the company recorded a gain from selling its nutritional products business to Swiss food group Nestle SA .

    Excluding special items, PFIZER (PFE.NY)earned 56 cents per share. Analysts, on average, expected 52 cents per share, according to Thomson Reuters I/B/E/S.

    (Reporting by Ransdell Pierson; editing by Sofina Mirza-Reid)